XML 90 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727
(LOSS) EARNINGS PER SHARE
 6 Months Ended
Jun. 30, 2015
Earnings Per Share [Abstract]  
(LOSS) EARNINGS PER SHARE
(LOSS) EARNINGS PER SHARE
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc. for the three-month and six-month periods ended June 30, 2015 and 2014 were calculated as follows:
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2015
 
2014
 
2015
 
2014
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.
$
(53.0
)
 
$
125.8

 
$
20.7

 
$
103.2

 
 
 
 
 
 
 
 
Basic weighted-average number of common shares outstanding
344.4

 
335.3

 
340.5

 
335.1

Diluted effect of stock options, RSUs and other(a)
—

 
6.0

 
6.6

 
6.3

Diluted weighted-average number of common shares outstanding
344.4

 
341.3

 
347.1

 
341.4

 
 
 
 
 
 
 
 
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.:
 
 
 
 
 
 
 
Basic
$
(0.15
)
 
$
0.38

 
$
0.06

 
$
0.31

Diluted
$
(0.15
)
 
$
0.37

 
$
0.06

 
$
0.30

____________________________________
(a)
In the three-month period ended June 30, 2015, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
 
 
Three Months
Ended
June 30,
 
 
2015
Basic weighted-average number of common shares outstanding
 
344.4

Diluted effect of stock options, RSUs and other
 
6.5

Diluted weighted-average number of common shares outstanding
 
350.9


In the three-month and six-month periods ended June 30, 2015, stock options to purchase approximately 92,000 common shares in both of the corresponding periods of the Company were not included in the computation of diluted (loss) earnings per share because the effect would have been anti-dilutive under the treasury stock method, compared with 915,000 common shares in both of the corresponding periods of 2014.